New FDA Leadership Roles | Tech & Drug Oversight Changes

HHS Seeks Tighter Agency Control

The Department of Health and Human Services is preparing to install two new deputy commissioner roles at the Food and Drug Administration. One position will focus on technology and the integration of artificial intelligence in healthcare. The other will oversee drug regulation. These planned additions mark a clear shift in how the agency manages its internal operations and regulatory duties.

The new roles will report directly to Heidi Overton. President Trump nominated Overton to lead the FDA, though she still awaits confirmation from the Senate. Sources familiar with the plan state that the additions are intended to grant the administration more influence over agency decisions. The agency has not yet made a formal announcement regarding the timeline or the final structure of these posts.

Potential Leadership Appointments

Industry experience appears to be a priority for the incoming leadership. Reports indicate that Jared Seehafer is the leading candidate for the technology deputy commissioner role. Seehafer currently serves as a senior advisor to the FDA and brings deep experience from the medical devices sector. He previously founded Enzyme, a firm specializing in life sciences compliance software. He also spent time at a venture capital firm based in San Francisco.

The search for a candidate to fill the drug-focused deputy position remains active. Officials have not shared potential names for that office. The FDA already maintains several deputy commissioners, including an acting head for food programs. It remains unclear how these new positions will intersect with current leadership hierarchies or if existing staff will shift roles to accommodate the change.

Agency Under Pressure

This expansion follows a period of intense scrutiny for the FDA. A recent multistate outbreak of cyclosporiasis tied to iceberg lettuce raised questions about the agency's ability to monitor food safety. Critics point to ongoing staff and budget cuts as primary reasons for recent lapses. The agency also faced significant backlash earlier this year after demanding a complex study for a Huntington’s disease treatment from UniQure, a decision regulators eventually reversed.

Technology is now a central part of the agency’s workload. Regulators at the FDA currently use an internal generative AI tool called Elsa for drafting documents and summarizing complex data. They are also tasked with evaluating medical devices that incorporate AI. The new deputy commissioner for technology will likely have oversight of both internal tool adoption and the external review process for new products. Last week, the agency issued a discussion paper asking for public feedback on how it should handle the regulation of AI-enabled devices. This request suggests a move toward more structured oversight in a fast-moving technical field.